ENCR

RL
by Raquel López González1 view·Updated Oct 29, 2021

Chapters

Audio TranscriptAuto-generated

  1. Good morning. My name is like a little bit.
  2. I am part of the population based cancer registry of Madrid
  3. and I'm here to present you the quality indicators of
  4. the newly established pediatric population based cancer registry of Madrid.
  5. As you may know,
  6. there are four aspects usually regarded when
  7. evaluating the quality of cancer registries,
  8. comparability, completeness validity and timeliness.
  9. It is important for cancer registries to analyze the quality of the data regularly.
  10. But perhaps it is even more important for newly established registries
  11. that are taking their first steps and pollution data
  12. as they need to establish their basis on robust, reliable and high quality data.
  13. The pediatric population-based cancer registry of Madrid
  14. was created in 2017 and it has focused its
  15. first efforts on analyzing data for traffic and adolescent cancers
  16. and it has already validated all tumors diagnosed a month
  17. 2015 and 2017 in people under 20 years old.
  18. With all of this,
  19. I was to evaluate the quality of the newly established
  20. pediatric population based cancer registry
  21. or graduate through quality indicators.
  22. A red streak collects information on all malignant tumors except non melanoma,
  23. skin cancers plus non malignant tumors of the sinus
  24. and benign and see two of the black.
  25. We reviewed manually and individually all the
  26. medical records available in the electronic,
  27. all clinical history.
  28. In search of clinical information.
  29. To analyze the quality of the data,
  30. we perform an internal coherence analysis to detect
  31. unlikely or impossible combinations of topographic morphological codes,
  32. unlikely thomas at certain natives
  33. and other verifications. Using the iron tools
  34. with an analyze the quality indicators proposed by the iron
  35. in their latest report
  36. and compared ourselves results with the accepted ranges.
  37. One of these indicators is the proportion of non malignant presence over
  38. the total number of central nervous system pleasant which we analyzed,
  39. taking into account the different behaviors of
  40. the pillow citicasters saitama in the video,
  41. which changes from malignant, too uncertain.
  42. In the third edition
  43. after this process, they were shown,
  44. the results showed that all the quality indicators were among the accepted rates.
  45. The proportion of cases eight several years.
  46. The microscopic microscopically sorry verified cases.
  47. The cases identified by the death certificate only the unspecified cases and
  48. the eight standardizes cases were within the range accepted by the I.
  49. R.
  50. On the other hand, we also found that the proportion of non malignant
  51. spasms
  52. may not be comparable across other registries
  53. or with earlier published data because the result
  54. changes quite a lot depending on which cost classification. Use.
  55. If you take a look at the red marked area in the table at the right,
  56. you can see that if you consider parasitic as to saitama non malignant,
  57. the result exceeds the accepted range.
  58. While if you consider it uncertain admits the standard
  59. Friendly, there are tools reported 17 warnings about unlikely combinations
  60. that we reviewed mentally. Again,
  61. we found them to be correct and we validated them as unusual or rare cancer cases.
  62. So
  63. to summer,
  64. we conclude that the quality indicators of the pediatric population base
  65. cancer registry of Madrid are similar to those
  66. provided by other european pediatric cancer registries,
  67. which suggests that our registry provides data with high validity
  68. and that the use of internationally recognized and validated tools
  69. enables the systematic analysis of data quality and its comparison.
  70. This is all. Thank you very much to the E. N. C. R.
  71. For the opportunity of presenting this poster in this
  72. meeting and thank you all for your attention.
  73. Goodbye.